title: Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs.
abstract: Use of highly pure antigens to improve vaccine safety has led to reduced vaccine immunogenicity and efficacy. This has led to the need to use adjuvants to improve vaccine immunogenicity. The ideal adjuvant should maximize vaccine immunogenicity without compromising tolerability or safety. Unfortunately, adjuvant research has lagged behind other vaccine areas such as antigen discovery, with the consequence that only a very limited number of adjuvants based on aluminium salts, monophosphoryl lipid A and oil emulsions are currently approved for human use. Recent strategic initiatives to support adjuvant development by the National Institutes of Health should translate into greater adjuvant choices in the future. Mechanistic studies have been valuable for better understanding of adjuvant action, but mechanisms of adjuvant toxicity are less well understood. The inflammatory or danger-signal model of adjuvant action implies that increased vaccine reactogenicity is the inevitable price for improved immunogenicity. Hence, adjuvant reactogenicity may be avoidable only if it is possible to separate inflammation from adjuvant action. The biggest remaining challenge in the adjuvant field is to decipher the potential relationship between adjuvants and rare vaccine adverse reactions, such as narcolepsy, macrophagic myofasciitis or Alzheimer's disease. While existing adjuvants based on aluminium salts have a strong safety record, there are ongoing needs for new adjuvants and more intensive research into adjuvants and their effects.
authors.affiliation: Department of Endocrinology and Diabetes, Flinders University, Adelaide, SA, 5042, Australia. nikolai.petrovsky@flinders.edu.au.|Vaxine Pty Ltd, Adelaide, SA, Australia. nikolai.petrovsky@flinders.edu.au.
authors.forename: Nikolai
authors.initials: N
authors.lastname: Petrovsky
mesh_terms: D000276:Adjuvants, Immunologic / Q000009:adverse effects* / Q000592:standards; D000818:Animals; D064420:Drug-Related Side Effects and Adverse Reactions / Q000175:diagnosis*; D005544:Forecasting; D006801:Humans; D014612:Vaccines / Q000009:adverse effects* / Q000592:standards
chemical_list: D000276:Adjuvants, Immunologic; D014612:Vaccines